Hannam & Partners, a leading independent investment bank, issued an independent research report on Psyence Group.
The report identifies the company as a first mover into the palliative care market supported by natural psilocybin production.
It notes that while Psyence has already generated revenue through its functional mushroom joint venture (Psyence Function) and production facility vertical (Psyence Production), it attributes the lion’s share of Psyence’s value to its drug discovery programme and expects a 450 per cent uplift in share price.
Psyence Group Inc. (PSYG) opened trading at C$0.10
